De Novo device
Phagenyx System
Phagenesis Limited · Oropharyngeal Electrical Stimulator (QQG, Class II) · First FDA decision Sep 16, 2022, newest Sep 16, 2022Stroke recovery and rehabilitation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
7
Naming "Phagenyx"
MAUDE reports
2
Brand "Phagenyx", since 2015
PubMed studies
2
Mentioning "Phagenyx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Phagenyx System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Phagenyx SystemNew device typeBreakthroughDe Novo
DEN220025 · Decided Sep 16, 2022 · 150 days after receipt
Device type: Oropharyngeal Electrical Stimulator (QQG) · Otolaryngology (ENT)
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Non-Implantable Pelvic Floor Electrical StimulatorNational determinationOn the books230.8Updated Aug 17, 2023
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Phagenyx", any status and sponsor, newest update first.
- Phagenyx® Registry StudyRecruiting
Phagenesis Ltd.Not on our public-company list
NCT06866418 · 600 participants (planned) · Start Sep 15, 2025 · Primary completion Sep 2035
Device: 1. Phagenyx® System Group Patients · For: Dysphagia
Sites: Phoenix, Arizona; Neptune City, New Jersey; Houston, Texas
Phagenesis Ltd.Not on our public-company list
NCT03840395 · 72 participants · Start Jun 17, 2019 · Primary completion Aug 1, 2025
Device: Pharyngeal Electrical Stimulation (PES) · For: Dysphagia
Sites: Innsbruck, Austria; Hamburg, Germany; Bern, Switzerland · 5 sites in all
Karl Landsteiner University of Health SciencesAcademic, hospital or other
NCT05190718 · 100 participants (planned) · Start Dec 15, 2021 · Primary completion Dec 1, 2025
Device: Pharyngeal electrostimulation · For: Neurogenic Dysphagia; Traumatic Brain Injury; Stroke and 4 more
Sites: Tulln, Austria
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Phagenyx", and for the whole product code for context.
This brand
2 reports: 1 malfunction, 0 injury, 1 death
Whole product code QQG
2 reports: 1 malfunction, 0 injury, 1 death
Newest reports for this brand
- PHAGENYXMalfunction
21696938 · Received Mar 26, 2025 · Event dated Jan 28, 2025
Device type: Oropharyngeal Electrical Stimulator (QQG)
Patient problem as coded: Cardiac Arrest; Diaphoresis; Respiratory Arrest; Alteration in Body Temperature
- PHAGENYXDeath
3014265054-2025-00001 · Received Mar 7, 2025 · Event dated Jan 28, 2025
Device type: Oropharyngeal Electrical Stimulator (QQG)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Aspiration/Inhalation
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Phagenyx"[tiab]. The summary above synthesizes these.
- Pharyngeal electrical stimulation for the treatment of dysphagia in Wallenberg syndrome: A FEES-based case analysis.
Hinkelmann F, Kaspari M, Wojtecki L · eNeurologicalSci · 2026Case Reports
- Therapy of Dysphagia by Prolonged Pharyngeal Electrical Stimulation (Phagenyx) in a Patient with Brainstem Infarction.
Florea C, Bräumann C, Mussger C, et al. · Brain Sci · 2020Case Reports
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.